NASDAQ:CCXIChemoCentryx Stock Price, Forecast & News

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CCXI shares have increased by 26.7% and is now trading at $52.64.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ChemoCentryx.

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for ChemoCentryx.

ChemoCentryx Inc (NASDAQ:CCXI) issued its earnings results on Monday, August, 10th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.63. ChemoCentryx had a negative return on equity of 47.56% and a negative net margin of 39.19%.
View ChemoCentryx's earnings history.

9 Wall Street analysts have issued twelve-month price objectives for ChemoCentryx's shares. Their forecasts range from $54.00 to $100.00. On average, they expect ChemoCentryx's stock price to reach $70.67 in the next twelve months. This suggests a possible upside of 34.2% from the stock's current price.
View analysts' price targets for ChemoCentryx.

Press coverage about CCXI stock has trended positive on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ChemoCentryx earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about ChemoCentryx.

ChemoCentryx saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,820,000 shares, an increase of 36.9% from the April 30th total of 2,060,000 shares. Based on an average daily volume of 678,900 shares, the days-to-cover ratio is currently 4.2 days. Currently, 6.4% of the shares of the company are sold short.
View ChemoCentryx's Short Interest.

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), Opko Health (OPK), Chesapeake Energy (CHKAQ) and Chesapeake Energy (CHKAQ).

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (16.44%), Vanguard Group Inc. (5.26%), Marshall Wace North America L.P. (2.51%), Wasatch Advisors Inc. (1.49%), Avidity Partners Management LP (0.94%) and Macquarie Group Ltd. (0.78%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall.
View institutional ownership trends for ChemoCentryx.

CCXI stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Mangrove Partners, Wasatch Advisors Inc., Canada Pension Plan Investment Board, EAM Investors LLC, Knott David M, Alps Advisors Inc., and WINTON GROUP Ltd. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx.

CCXI stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., FMR LLC, Avidity Partners Management LP, Marshall Wace North America L.P., Marshall Wace LLP, Monashee Investment Management LLC, Macquarie Group Ltd., and Healthcare of Ontario Pension Plan Trust Fund.
View insider buying and selling activity for ChemoCentryx.

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CCXI stock can currently be purchased for approximately $52.64.

ChemoCentryx has a market capitalization of $3.63 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

The official website for ChemoCentryx is www.chemocentryx.com.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]